

## Biology of Blood and Marrow Transplantation

journal homepage: www.bbmt.org



# Outcomes of Influenza Infections in Hematopoietic Cell Transplant Recipients: Application of an Immunodeficiency Scoring Index



Joumana Kmeid<sup>1</sup>, Jakapat Vanichanan<sup>1</sup>, Dimpy P. Shah<sup>1</sup>, Firas El Chaer<sup>1</sup>, Jacques Azzi<sup>1</sup>, Ella J. Ariza-Heredia<sup>1</sup>, Chitra Hosing<sup>2</sup>, Victor Mulanovich<sup>1</sup>, Roy F. Chemaly<sup>1,\*</sup>

<sup>1</sup> Department of Infectious Diseases, Infection Control, and Employee Health, University of Texas MD Anderson Cancer Center, Houston, Texas <sup>2</sup> Department of Stem Cell Transplantation and Cellular Therapy, University of Texas MD Anderson Cancer Center, Houston, Texas

Article history: Received 12 October 2015 Accepted 20 November 2015

Key words: Influenza Antiviral therapy Scoring index Immunocompromised Cancer

## ABSTRACT

Hematopoietic cell transplant (HCT) recipients have lower immune response to influenza vaccination and are susceptible to lower respiratory tract infection (LRI) and death. We determined clinical characteristics and outcomes of laboratory-confirmed influenza, including 2014/H3N2 infection, in 146 HCT recipients. An immunodeficiency scoring index (ISI) was applied to identify patients at high risk for LRI and death. Thirty-three patients (23%) developed LRI and 7 (5%) died within 30 days of diagnosis. Most patients received antiviral therapy (83%); however, only 18% received it within 48 hours of symptom onset. The incidence of LRI was significantly higher in the ISI high-risk group than it was in the low-risk group (P < .001). Receiving early antiviral therapy was associated with a substantial reduction in LRI for all ISI risk groups with the greatest risk reduction observed in the high-risk group. When compared with previous seasons, no significant differences in patient outcomes were observed during the 2014/H3N2 season; however, antiviral therapy was more promptly initiated in the latter season. The ISI that was originally developed for respiratory syncytial virus may help identify HCT recipients at risk for progression to LRI and mortality after influenza infection. These patients should be monitored more closely. Early initiation of antiviral therapy for influenza in HCT recipients, regardless of the ISI risk group, may improve morbidity as well as mortality.

© 2016 American Society for Blood and Marrow Transplantation.

## **INTRODUCTION**

The severity of influenza infection in the general population depends on vaccination uptake and the main circulating virus, among other factors. Some seasons, such as the 2009/H1N1 pandemic season, have had higher rates of hospitalizations (274,000 hospitalizations in the United States alone); however, disease severity in that season was not significantly different from that in previous seasons [1,2]. The severity of influenza infection also depends on the host immune status and its underlying risk factors. Multiple studies have shown that susceptible populations, such as children, the elderly, pregnant women, solid-organ transplant recipients, and hematopoietic cell transplant (HCT) recipients, have higher risk of developing severe disease and higher rates of complications, such as hospitalizations, prolonged viral shedding, emergence of viral resistance, and mortality, than the general population [3-7].

Influenza infection in HCT recipients has been increasingly recognized as a serious infection with severe implications [8-10]. In fact, it is 1 of the most common respiratory viral infections (influenza accounts for 30% of all respiratory viral infections) and it causes increased morbidity and mortality in this population. Up to 35% of these patients progress to lower respiratory tract infection (LRI) with subsequent high mortality [10,11]. Previous studies have revealed various risk factors for influenza-associated LRI in HCT recipients, such as lymphocytopenia, nosocomial acquisition of the virus, older age, and pre-existing lung disease [12-14]. Using these clinically available risk factors, an immunodeficiency scoring index (ISI) was developed in HCT recipients with respiratory syncytial virus (RSV) infections to help identify patients at higher risk for complications and those who would benefit the most from antiviral therapy [15]. As this

Financial disclosure: See Acknowledgments on page 547.

<sup>\*</sup> Correspondence and reprint requests: Roy F. Chemaly, MD, MPH, Department of Infectious Diseases, Infection Control, and Employee Health, Unit 402, University of Texas MD Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030-4009.

E-mail address: rfchemaly@mdanderson.org (R.F. Chemaly).

#### Table 1

Clinical Characteristics and Outcomes of Influenza Infections in 146 HCT Recipients (N = 146)

Age, median (range), yr     52 (14-80)       Sex     77 (53)       Male     77 (53)       Fernale     69 (47)       Race     77 (12)       Hispanic     34 (23)       Other     87 (60)       Black     17 (12)       Hispanic     34 (23)       Other     8 (5)       Domor relationship     10 (7)       Matched related     36 (23)       Mismatched     10 (7)       Autologous     52 (36)       HCT cell source     7       Peripheral     111 (76)       Marrow     29 (20)       Cord     2 (1)       Time from HCT to inflection     398 (2-7140)       Acute CVHD     11 (8)       Chronic CVHD     29 (20)       Cord     21 (1)       Iymphoma     29 (20)       Other     48 (33)       Cancer status at the time of infection     Remission       Remission     115 (79)       Active/relapse     31 (21)       Myeloablative conditioning regimen (past 100 days) <th>Characteristic</th> <th>Value</th>	Characteristic	Value
Male     77 (53)       Female     69 (47)       Race     87 (60)       Black     17 (12)       Hispanic white     87 (60)       Black     17 (12)       Hispanic     34 (23)       Other     86 (5)       Donor relationship     44 (23)       Matched related     50 (34)       Matched related     10 (7)       Autologous     52 (36)       HCT cell source     7       Peripheral     111 (76)       Marrow     29 (20)       Cord     2 (1)       Time from HCT to inflection     98 (2-7140)       Acute GVHD     11 (8)       Chronic GVHD     29 (20)       Cord     2 (1)       Ime from HCT to inflection     86 (37)       Leukemia     69 (47)       Lymphoma     29 (20)       Other     48 (33)       Cancer status at the time of infection     Remission       Remission     115 (79)       Attive/relapse     31 (21)       Myeloablative conditioning regimen (past 100 days		52 (14-80)
Female69 (47)RaceNon-Hispanic white87 (60)Black17 (12)Hispanic34 (23)Other8 (5)Domor relationship8 (5)Matched related34 (23)Mismatched34 (23)Mismatched34 (23)Mismatched34 (23)Mismatched34 (23)Mismatched34 (23)Mismatched34 (23)Mismatched111 (76)Marrow29 (20)Cord2 (1)Time from HCT to infection27 (18)Underlying malignancy11 (8)Leukemia69 (47)Lymphoma29 (20)Other48 (33)Cancer status at the time of infection83Remission11 5 (79)Active C/Plapse31 (21)Myeloablative conditioning regimen (past 100 days)17 (12)Corticosteroids within 30 days of diagnosis46 (32)Smoking history11 (8)Never118 (8)Never13 (21)Myeloablative conditioning regimen (past 100 days)17 (12)Current118 (8)BMI, median (range), kg/m²27 (15-63)BMI categories (WHO classification)11 (8)Underweight: <18.5		77 (52)
RaceNon-Hispanic white87 (60)Black17 (12)Hispanic34 (23)Other8 (5)Donor relationship8 (5)Matched unrelated34 (23)Matched unrelated34 (23)Mismatched10 (7)Autologous52 (36)HCT cell source2 (20)Cord2 (1)Time from HCT to infection11 (8)Median (range), d398 (2-7140)Acute GVHD11 (8)Chronic CVHD27 (18)Underlying malignancy29 (20)Cord27 (18)Underlying malignancy27 (18)Leukemia69 (47)Lymphoma29 (20)Other48 (33)Cancer status at the time of infection71 (12)Corticosteroids within 30 days of diagnosis46 (32)Smoking history17 (12)Corticosteroids within 30 days of diagnosis46 (32)Smoking history11 (18)BM, median (range), kg/m²27 (15-63)BM (ategories (WHO classification)11 (18)Underweight: <18.5		
Back17 (12)Hispanic34 (23)Other8 (5)Donor relationship*********************************	Race	
Hispanic $34 (23)$ 0 (23) Other $8 (5)$ Donor relationship8 (5)Matched related $50 (34)$ Matched unrelated $34 (23)$ MismatchedMismatched $10 (7)$ Autologous $52 (36)$ HCT cell sourcePeripheral $111 (76)$ MarrowPeripheral $111 (76)$ Marrow $29 (20)$ CordCord $2 (1)$ Time from HCT to infectionMedian (range), d $398 (2-7140)$ Actute CVHD $11 (8)$ Chronic GVHD $27 (18)$ Underlying malignancy $29 (20)$ CordLeukemia $69 (47)$ LymphomaQ (20) $21 (18)$ Cancer status at the time of infection $7(12)$ Remission $115 (79)$ Active/relapseMyeloablative conditioning regimen (past 100 days) $17 (12)$ Corricosteroids within 30 days of diagnosis $46 (32)$ Smoking history $V$ Never $103 (71)$ Former $22 (22)$ CurrentUnderweight: <18.5	-	
Other     8 (5)       Donor relationship		
Donor relationship     50 (34)       Matched related     34 (23)       Mismatched     10 (7)       Autologous     52 (36)       HCT cell source     29 (20)       Cord     2 (1)       Time from HCT to infection     398 (2-7140)       Actue GVHD     11 (8)       Chronic GVHD     11 (8)       Underlying malignancy     111 (76)       Leukemia     69 (47)       Lymphoma     29 (20)       Other     48 (33)       Cancer status at the time of infection     8 (33)       Cancer status at the time of infection     115 (79)       Active/relapse     31 (21)       Myeloablative conditioning regimen (past 100 days)     17 (12)       Corticosteroids within 30 days of diagnosis     46 (32)       Smoking history     Vever       Never     103 (71)       Former     32 (22)       Current     11 (8)       BMI, ategories (WHO classification)     Underweight: <18.5	-	
Matched unrelated     34 (23)       Mismatched     10 (7)       Autologous     52 (36)       HCT cell source     2       Peripheral     111 (76)       Marrow     29 (20)       Cord     2 (1)       Time from HCT to infection     Median (range), d       Median (range), d     398 (2-7140)       Acute CVHD     11 (8)       Chronic GVHD     27 (18)       Underlying malignancy		0(0)
Mismatched     10 (7)       Autologous     52 (36)       HCT cell source     Peripheral     111 (76)       Marrow     29 (20)     Cord     2 (1)       Time from HCT to infection     398 (2-7140)     Acute GVHD     11 (8)       Chronic GVHD     27 (18)     Underlying malignancy     Leukemia     69 (47)       Lymphoma     29 (20)     Other     48 (33)       Cancer status at the time of infection     Remission     115 (79)       Active/relapse     31 (21)     Myeloablative conditioning regimen (past 100 days)     17 (12)       Corticosteroids within 30 days of diagnosis     46 (32)     Smoking history       Never     103 (71)     Former     32 (22)       Current     11 (8)     BMI     BMI (median (range), kg/m²     27 (15-63)       BMI, median (range), kg/m²     27 (15-63)     50 (3)     Normal: 18.5-24.99     39 (27)       Overweight: 25-29.99     51 (35)     Obes: ≥ 30     50 (3H)       Imfection site at diagnosis     11 (9 (82)     RI       Laboratory abnormalities at presentation:     Leukerlagnosis     10 (7)		
Autologous     52 (36)       HCT cell source		
HCT cell sourceIII (76)Peripheral111 (76)Marrow29 (20)Cord2 (1)Time from HCT to infectionMedian (range), dMedian (range), d398 (2-7140)Acute CVHD11 (8)Chronic GVHD27 (18)Underlying malignancy29 (20)Leukemia69 (47)Lymphoma29 (20)Other48 (33)Cancer status at the time of infection88 (33)Remission115 (79)Active/relapse31 (21)Myeloablative conditioning regimen (past 100 days)17 (12)Corticosteroids within 30 days of diagnosis46 (32)Smoking history118 (8)Never103 (71)Former32 (22)Current11 (8)BMI, median (range), kg/m²27 (15-63)BMI categories (WHO classification)Underweight: <18.5		
Marrow     29 (20)       Cord     2 (1)       Time from HCT to infection     398 (2-7140)       Actue GVHD     11 (8)       Chronic GVHD     27 (18)       Underlying malignancy     29 (20)       Leukemia     69 (47)       Lymphoma     29 (20)       Other     48 (33)       Cancer status at the time of infection     Remission       Remission     115 (79)       Active/relapse     31 (21)       Myeloablative conditioning regimen (past 100 days)     17 (12)       Corticosteroids within 30 days of diagnosis     46 (32)       Smoking history     Never     103 (71)       Former     32 (22)     Current       Underweight: <18.5		52 (55)
Cord     2 (1)       Time from HCT to infection     998 (2-7140)       Acute GVHD     11 (8)       Chronic GVHD     27 (18)       Underlying malignancy     29 (20)       Leukemia     69 (47)       Lymphoma     29 (20)       Other     48 (33)       Cancer status at the time of infection     86 (33)       Remission     115 (79)       Active/relapse     31 (21)       Myeloablative conditioning regimen (past 100 days)     71 (12)       Corticosteroids within 30 days of diagnosis     46 (32)       Smoking history     Never     103 (71)       Former     32 (22)     201       Current     11 (8)     BMI categories (WHO classification)       Underweight: 28-29.99     51 (35)       Obese: ≥ 30     50 (34)       Time from symptoms onset to presentation     Median (range), d       URI     119 (82)       URI     119 (81)		
Time from HCT to infection Median (range), d398 (2-7140)Acute CVHD11 (8)Chronic CVHD27 (18)Underlying malignancy Leukemia69 (47)Lymphoma29 (20)Other48 (33)Cancer status at the time of infection Remission115 (79)Active/relapse31 (21)Myeloablative conditioning regimen (past 100 days)17 (12)Corticosteroids within 30 days of diagnosis46 (32)Smoking historyNever103 (71)Former32 (22)Current11 (8)BMI, median (range), kg/m²27 (15-63)BMI categories (WHO classification)Underweight: <18.5		
Median (range), d     398 (2-7140)       Acture GVHD     11 (8)       Chronic GVHD     27 (18)       Underlying malignancy     69 (47)       Leukemia     69 (47)       Lymphoma     29 (20)       Other     48 (33)       Cancer status at the time of infection     7       Remission     115 (79)       Active/relapse     31 (21)       Myeloablative conditioning regimen (past 100 days)     17 (12)       Corticosteroids within 30 days of diagnosis     46 (32)       Smoking history     118 (8)       Never     103 (71)       Former     32 (22)       Current     11 (8)       BMI, median (range), kg/m²     27 (15-63)       BMI categories (WHO classification)     10       Underweight: <18.5		2(1)
Chronic GVHD27 (18)Underlying malignancy $=$ Leukemia69 (47)Lymphoma29 (20)Other48 (33)Cancer status at the time of infection $=$ Remission115 (79)Active/relapse31 (21)Myeloablative conditioning regimen (past 100 days)17 (12)Corticosteroids within 30 days of diagnosis46 (32)Smoking history $=$ Never103 (71)Former32 (22)Current118 (8)BMI, median (range), kg/m²27 (15-63)BMI categories (WHO classification) $=$ Underweight: <18.5		398 (2-7140)
Underlying malignancy Leukemia $69$ (47) Lymphoma $29$ (20) Other $48$ (33)Cancer status at the time of infection Remission $115$ (79) Active/relapse $31$ (21)Myeloablative conditioning regimen (past 100 days) $17$ (12)Corticosteroids within 30 days of diagnosis $46$ (32)Smoking history $Ver$ $103$ (71)Former $32$ (22) Current $11$ (8)BMI, median (range), kg/m² $27$ (15-63)BMI categories (WHO classification) $Underweight: <18.5$ $5$ (3)Normal: 18.5-24.99 $39$ (27)Overweight: 25-29.99 $51$ (35)Obese: $\geq 30$ $50$ (34)Time from symptoms onset to presentation Median (range), d $2$ (0-21)Infection site at diagnosis $119$ (82)LRI $27$ (18)Laboratory abnormalities at presentation: Leukocytosis (WBC >11,000/mm) $8$ (5)Neutropenia (ANC <500 cells/mL)		
Leukemia     69 (47)       Lymphoma     29 (20)       Other     48 (33)       Cancer status at the time of infection     Remission       Remission     115 (79)       Active/relapse     31 (21)       Myeloablative conditioning regimen (past 100 days)     17 (12)       Corticosteroids within 30 days of diagnosis     46 (32)       Smoking history     Vever       Never     103 (71)       Former     32 (22)       Current     11 (8)       BMI, median (range), kg/m²     27 (15-63)       BMI categories (WHO classification)     Underweight: <18.5		27 (18)
Lymphoma29 (20) Other48 (33)Cancer status at the time of infectionRemission115 (79) Active/relapse31 (21)Myeloablative conditioning regimen (past 100 days)17 (12)Corticosteroids within 30 days of diagnosis46 (32)Smoking history103 (71)Former32 (22)Current11 (8)BMI, median (range), kg/m²27 (15-63)BMI categories (WHO classification)118, 5-24, 99Underweight: <25-29,99		69 (47)
Other48 (33)Cancer status at the time of infectionRemission115 (79)Active/relapse31 (21)Myeloablative conditioning regimen (past 100 days)17 (12)Corticosteroids within 30 days of diagnosis46 (32)Smoking historyNever103 (71)Former32 (22)Current11 (8)BMI, median (range), kg/m²27 (15-63)BMI categories (WHO classification)Underweight: <18.5		
Remission115 (79) Active/relapse31 (21)Myeloablative conditioning regimen (past 100 days)17 (12)Corticosteroids within 30 days of diagnosis46 (32)Smoking history103 (71)Former32 (22)Current118 (8)BMI, median (range), kg/m²27 (15-63)BMI categories (WHO classification)10Underweight: <18.5		48 (33)
Active/relapse31 (21)Myeloablative conditioning regimen (past 100 days)17 (12)Corticosteroids within 30 days of diagnosis46 (32)Smoking historyNever103 (71)Former32 (22)Current11 (8)BMI, median (range), kg/m²27 (15-63)BMI categories (WHO classification)Underweight: <18.5		115 (70)
Myeloablative conditioning regimen (past 100 days)17 (12)Corticosteroids within 30 days of diagnosis46 (32)Smoking history103 (71)Never103 (71)Former32 (22)Current11 (8)BMI, median (range), kg/m²27 (15-63)BMI categories (WHO classification)Underweight: <18.5		
Corticosteroids within 30 days of diagnosis $46 (32)$ Smoking historyNever $103 (71)$ Former $32 (22)$ Current $11 (8)$ BMI, median (range), kg/m² $27 (15-63)$ BMI categories (WHO classification)Underweight: <18.5		
Never103 (71)Former32 (22)Current11 (8)BMI, median (range), kg/m227 (15-63)BMI, categories (WHO classification)Underweight: <18.5	Corticosteroids within 30 days of diagnosis	
Former $32 (22)$ CurrentCurrent11 (8)BMI, median (range), kg/m²27 (15-63)BMI categories (WHO classification)Underweight: <18.5		100 (51)
Current11 (8)BMI, median (range), kg/m227 (15-63)BMI categories (WHO classification)Underweight: <18.5		
BMI, median (range), kg/m2 $27 (15-63)$ BMI categories (WHO classification)Underweight: <18.5		
Underweight: <18.55 (3)Normal: 18.5-24.9939 (27)Overweight: 25-29.9951 (35)Obese: ≥ 3050 (34)Time from symptoms onset to presentationMedian (range), d2 (0-21)Infection site at diagnosis119 (82)LRURI119 (82)LRLaboratory abnormalities at presentation:2 (0-21)Leukocytosis (WBC >11,000/mm)8 (5)Neutropenia (ANC <500 cells/mL)		
Normal: 18.5-24.99 $39(27)$ Overweight: 25-29.99 $51(35)$ Obese: $\geq 30$ $50(34)$ Time from symptoms onset to presentationMedian (range), dMedian (range), d $2(0-21)$ Infection site at diagnosis $27(18)$ URI $119(82)$ LRI $27(18)$ Laboratory abnormalities at presentation: $2(0-21)$ Leukocytosis (WBC >11,000/mm) $8(5)$ Neutropenia (ANC <500 cells/mL)		- (0)
Overweight: 25-29.99 $51(35)$ Obese: $\geq 30$ $50(34)$ Time from symptoms onset to presentationMedian (range), d $2(0-21)$ Infection site at diagnosis $119(82)$ URI $119(82)$ LRI $27(18)$ Laboratory abnormalities at presentation: $2(0-21)$ Leukocytosis (WBC >11,000/mm) $8(5)$ Neutropenia (ANC <500 cells/mL)		
Obese: $\geq 30$ 50 (34)Time from symptoms onset to presentation Median (range), d2 (0-21)Infection site at diagnosis119 (82)URI27 (18)Laboratory abnormalities at presentation: Leukocytosis (WBC >11,000/mm)8 (5)Neutropenia (ANC <500 cells/mL)		
Median (range), d $2 (0-21)$ Infection site at diagnosis119 (82)URI119 (82)LRI27 (18)Laboratory abnormalities at presentation:10Leukocytosis (WBC >11,000/mm)8 (5)Neutropenia (ANC <500 cells/mL)		
Infection site at diagnosisURI119 (82)LRI27 (18)Laboratory abnormalities at presentation:27 (18)Leukocytosis (WBC >11,000/mm)8 (5)Neutropenia (ANC <500 cells/mL)		2 (0.21)
URI119 (82)LRI27 (18)Laboratory abnormalities at presentation:27 (18)Leukocytosis (WBC >11,000/mm)8 (5)Neutropenia (ANC <500 cells/mL)		2(0-21)
Laboratory abnormalities at presentation:Leukocytosis (WBC >11,000/mm)8 (5)Neutropenia (ANC <500 cells/mL)		119 (82)
Leukocytosis (WBC >11,000/mm)8 (5)Neutropenia (ANC <500 cells/mL)	LRI	27 (18)
Neutropenia (ANC <500 cells/mL)10 (7)Lymphocytopenia (ALC <200 cells/mL)		0 (5)
Lymphocytopenia (ALC <200 cells/mL)11 (8)Elevated creatinine (>1.3 mg/dL)23 (16)Decreased albumin (<3.5 g/dL)		
Elevated creatinine (>1.3 mg/dL)23 (16)Decreased albumin (<3.5 g/dL)		
Hypoxia at diagnosis10 (7)Coinfections (within 1 month of diagnosis)22 (15)Respiratory copathogens16 (11)Outcomes16 (11)Progression from URI to LRI6/119 (5)Overall LRI33 (23)Admission to the hospital62 (42)Length of stay7 (1-74)ICU admission3 (2)Later9 (6)Mechanical ventilation7 (5)Oxygen supplement22 (15)Antiviral therapy38 (26)Within 48 hours of signosis38 (26)Death within 30 days from date of diagnosis7 (5)		
Coinfections (within 1 month of diagnosis)22 (15)Respiratory copathogens16 (11)Outcomes16 (11)Progression from URI to LRI6/119 (5)Overall LRI33 (23)Admission to the hospital62 (42)Length of stay7 (1-74)ICU admission3 (2)Later9 (6)Mechanical ventilation7 (5)Oxygen supplement22 (15)Antiviral therapy38 (26)Within 48 hours of symptoms onset26 (18)Within 48 hours of diagnosis38 (26)Death within 30 days from date of diagnosis7 (5)		
Respiratory copathogens16 (11)OutcomesProgression from URI to LRI6/119 (5)Overall LRI33 (23)Admission to the hospital62 (42)Length of stayMedian (range), d7 (1-74)ICU admission3 (2)Later9 (6)Mechanical ventilation7 (5)Oxygen supplement22 (15)Antiviral therapy38 (26)Within 48 hours of symptoms onset26 (18)Within 48 hours of diagnosis38 (26)Death within 30 days from date of diagnosis7 (5)		
Outcomes6/119 (5)Progression from URI to LRI6/119 (5)Overall LRI33 (23)Admission to the hospital62 (42)Length of stay7 (1-74)ICU admission7 (1-74)ICU admission3 (2)Later9 (6)Mechanical ventilation7 (5)Oxygen supplement22 (15)Antiviral therapyAnytime during the episodeWithin 48 hours of symptoms onset26 (18)Within 48 hours of diagnosis38 (26)Death within 30 days from date of diagnosis7 (5)		
Overall LRI33 (23)Admission to the hospital62 (42)Length of stay7 (1-74)ICU admission3 (2)Later9 (6)Mechanical ventilation7 (5)Oxygen supplement22 (15)Antiviral therapy121 (83)Within 48 hours of symptoms onset26 (18)Within 48 hours of diagnosis38 (26)Death within 30 days from date of diagnosis7 (5)	Outcomes	
Admission to the hospital62 (42)Length of stay7 (1-74)ICU admission3 (2)Later9 (6)Mechanical ventilation7 (5)Oxygen supplement22 (15)Antiviral therapy4nytime during the episodeMithin 48 hours of symptoms onset26 (18)Within 48 hours of diagnosis38 (26)Death within 30 days from date of diagnosis7 (5)	•	
Length of stayMedian (range), d7 (1-74)ICU admission3 (2)On admission3 (2)Later9 (6)Mechanical ventilation7 (5)Oxygen supplement22 (15)Antiviral therapy22 (15)Anytime during the episode121 (83)Within 48 hours of symptoms onset26 (18)Within 48 hours of diagnosis38 (26)Death within 30 days from date of diagnosis7 (5)		, ,
Median (range), d7 (1-74)ICU admission3 (2)On admission3 (2)Later9 (6)Mechanical ventilation7 (5)Oxygen supplement22 (15)Antiviral therapy22 (15)Anytime during the episode121 (83)Within 48 hours of symptoms onset26 (18)Within 48 hours of diagnosis38 (26)Death within 30 days from date of diagnosis7 (5)		02 (42)
On admission3 (2)Later9 (6)Mechanical ventilation7 (5)Oxygen supplement22 (15)Antiviral therapy121 (83)Within 48 hours of symptoms onset26 (18)Within 48 hours of diagnosis38 (26)Death within 30 days from date of diagnosis7 (5)		7 (1-74)
Later9 (6)Mechanical ventilation7 (5)Oxygen supplement22 (15)Antiviral therapy22 (15)Anytime during the episode121 (83)Within 48 hours of symptoms onset26 (18)Within 48 hours of diagnosis38 (26)Death within 30 days from date of diagnosis7 (5)		2 (2)
Mechanical ventilation7 (5)Oxygen supplement22 (15)Antiviral therapy22 (15)Anytime during the episode121 (83)Within 48 hours of symptoms onset26 (18)Within 48 hours of diagnosis38 (26)Death within 30 days from date of diagnosisAll-cause mortality7 (5)		. ,
Oxygen supplement22 (15)Antiviral therapy121 (83)Anytime during the episode121 (83)Within 48 hours of symptoms onset26 (18)Within 48 hours of diagnosis38 (26)Death within 30 days from date of diagnosisAll-cause mortality7 (5)		
Anytime during the episode121 (83)Within 48 hours of symptoms onset26 (18)Within 48 hours of diagnosis38 (26)Death within 30 days from date of diagnosisAll-cause mortality7 (5)	Oxygen supplement	. ,
Within 48 hours of symptoms onset26 (18)Within 48 hours of diagnosis38 (26)Death within 30 days from date of diagnosisAll-cause mortality7 (5)		101 (62)
Within 48 hours of diagnosis38 (26)Death within 30 days from date of diagnosis38 (26)All-cause mortality7 (5)		
Death within 30 days from date of diagnosis All-cause mortality 7 (5)	Within 48 hours of diagnosis	
Influenza-related death 6 (4)		
	influenza-related death	6(4)

scoring index was not based on virus-specific factors, it may be extrapolated to other respiratory viruses, such as influenza, in HCT recipients.

In this study, we aimed to compare the clinical characteristics and outcomes of influenza infection, including the pandemic 2009/H1N1, strains from the subsequent seasons, and the current 2014/H3N2 influenza strain in HCT recipients, especially in view of the reported decreased efficacy of the 2014-2015 influenza vaccine (the main circulating virus during the past season was influenza A/2014/H3N2, which was a drifted strain that was not included in the current vaccine) [16]. We also applied the ISI to stratify HCT recipients according to their risk of severe influenza infection to compare their probabilities for serious complications such as LRI and death.

#### MATERIALS AND METHODS

We conducted a retrospective study and included all HCT recipients with laboratory-confirmed influenza infection from July 2009 to December 2013 at the University of Texas MD Anderson Cancer Center in Houston, Texas. The institutional review board approved the protocol and waived the requirement for obtaining informed consent.

We also examined the clinical characteristics and outcomes of patients with 2014/H3N2 influenza A infections from November 2014 to December 2014 and compared those with the 4 previous seasons. We collected the following data from medical chart review: demographic information including age, sex, race, body mass index (BMI), and smoking status; cancer type; type of HCT; time from HCT to influenza infection; type of conditioning regimen; use of myeloablative regimen within 100 days before the diagnosis of influenza infection; coinfections; use of immunosuppressive therapy within the month preceding the diagnosis of influenza A infection; and detailed information on clinical characteristics, laboratory test results, and radiologic characteristics upon presentation. Data about treatment and the outcomes, such as length of hospital stay, development of LRI, admission to intensive care unit, mechanical ventilation, oxygen supplementation, and death, were also recorded.

#### Definitions

An influenza case was defined as any HCT recipient who developed acute respiratory illness and had influenza confirmed via viral culture and/or a direct fluorescent antigen test. The polymerase chain reaction (PCR) assay was only available and used during the 2014/H3N2 influenza season. Upper respiratory tract infection (URI) was defined as the onset of any of the following symptoms: fever, cough, rhinorrhea, sore throat, earache, or nasal or sinus congestion with a normal or unchanged chest radiograph or chest computed tomography scan at the time of influenza virus infection confirmed via nasal wash. LRI was defined as the onset of any of the previous symptoms with chest imaging (chest radiograph or chest computed tomography scan) demonstrating new or worsening pulmonary infiltrates suggestive of viral infection at the time of influenza virus infection confirmed via any respiratory specimen, including nasal wash, sputum, bronchoalveolar washing or lavage, or endotracheal tube aspirate. A nosocomial infection was defined as the onset of respiratory symptoms at least 48 hours after admission. Severe neutropenia was defined as an absolute neutrophil count of < 500 cells/mL, and severe lymphocytopenia was defined as an absolute lymphocyte count of < 200 cells/mL. All-cause mortality was defined as death from any cause within 30 days of the diagnosis of influenza infection, and mortality was attributed to influenza if a persistent or progressive influenza infection with respiratory failure was present at the time of death. Antiviral therapy was considered to be early if it were started within 48 hours of diagnosis.

#### ISI

In a previous study [15], we developed an ISI in HCT recipients with RSV infection, using variables related to the host such as age, low neutrophil and lymphocyte counts, the nature of the conditioning regimen used, time from transplantation, the presence of complications such as graft-versus-host disease, and corticosteroid use (Supplemental Table). This scoring index

Data presented are n (%), unless otherwise indicated.

GVHD indicates graft-versus-host disease; WHO, World Health Organization; ANC, absolute neutrophil count; ALC, absolute lymphocyte count; ICU, intensive care unit.

Download English Version:

# https://daneshyari.com/en/article/2101809

Download Persian Version:

https://daneshyari.com/article/2101809

Daneshyari.com